Lixte Biotechnology Holdings Stock Current Valuation
| LIXT Stock | USD 1.30 0.01 0.76% |
Valuation analysis of Lixte Biotechnology helps investors to measure Lixte Biotechnology's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. At this time, Lixte Biotechnology's Enterprise Value Over EBITDA is comparatively stable compared to the past year. Enterprise Value Multiple is likely to gain to 85.40 in 2025, despite the fact that Enterprise Value is likely to grow to (5 M). Fundamental drivers impacting Lixte Biotechnology's valuation include:
Overvalued
Today
Please note that Lixte Biotechnology's price fluctuation is extremely dangerous at this time. Calculation of the real value of Lixte Biotechnology is based on 3 months time horizon. Increasing Lixte Biotechnology's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Lixte Biotechnology's intrinsic value may or may not be the same as its current market price of 1.30, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.3 | Real 1.25 | Hype 1.32 | Naive 1.32 |
The intrinsic value of Lixte Biotechnology's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Lixte Biotechnology's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Lixte Biotechnology Holdings helps investors to forecast how Lixte stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Lixte Biotechnology more accurately as focusing exclusively on Lixte Biotechnology's fundamentals will not take into account other important factors: Lixte Biotechnology Holdings Company Current Valuation Analysis
Lixte Biotechnology's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Lixte Biotechnology Current Valuation | 5.35 M |
Most of Lixte Biotechnology's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Lixte Biotechnology Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Lixte Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Lixte Biotechnology is extremely important. It helps to project a fair market value of Lixte Stock properly, considering its historical fundamentals such as Current Valuation. Since Lixte Biotechnology's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Lixte Biotechnology's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Lixte Biotechnology's interrelated accounts and indicators.
Click cells to compare fundamentals
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Lixte Biotechnology Holdings has a Current Valuation of 5.35 M. This is 99.96% lower than that of the Biotechnology sector and 99.88% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.97% higher than that of the company.
Lixte Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Lixte Biotechnology's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Lixte Biotechnology could also be used in its relative valuation, which is a method of valuing Lixte Biotechnology by comparing valuation metrics of similar companies.Lixte Biotechnology is currently under evaluation in current valuation category among its peers.
Lixte Fundamentals
| Return On Equity | -1.27 | ||||
| Return On Asset | -0.72 | ||||
| Current Valuation | 5.35 M | ||||
| Shares Outstanding | 2.68 M | ||||
| Shares Owned By Insiders | 18.71 % | ||||
| Shares Owned By Institutions | 15.75 % | ||||
| Number Of Shares Shorted | 55.52 K | ||||
| Price To Earning | (2.96) X | ||||
| Price To Book | 12.00 X | ||||
| EBITDA | 3.21 K | ||||
| Net Income | (5.09 M) | ||||
| Cash And Equivalents | 7.74 M | ||||
| Cash Per Share | 0.47 X | ||||
| Total Debt | 313.86 K | ||||
| Debt To Equity | 0.16 % | ||||
| Current Ratio | 15.10 X | ||||
| Book Value Per Share | (0.95) X | ||||
| Cash Flow From Operations | (4.29 M) | ||||
| Short Ratio | 0.30 X | ||||
| Earnings Per Share | (1.72) X | ||||
| Beta | 0.19 | ||||
| Market Capitalization | 3.52 M | ||||
| Total Asset | 4.31 M | ||||
| Retained Earnings | (48.48 M) | ||||
| Working Capital | 3.99 M | ||||
| Current Asset | 1.38 M | ||||
| Current Liabilities | 140 K | ||||
| Net Asset | 4.31 M |
About Lixte Biotechnology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Lixte Biotechnology Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lixte Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lixte Biotechnology Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Lixte Stock Analysis
When running Lixte Biotechnology's price analysis, check to measure Lixte Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lixte Biotechnology is operating at the current time. Most of Lixte Biotechnology's value examination focuses on studying past and present price action to predict the probability of Lixte Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lixte Biotechnology's price. Additionally, you may evaluate how the addition of Lixte Biotechnology to your portfolios can decrease your overall portfolio volatility.